REVOLUTION MEDICINES INC (RVMD) Stock Price, Forecast & Analysis
NASDAQ:RVMD • US76155X1000
RVMD Key Statistics, Chart & Performance
The current stock price of RVMD is 96.31 USD. In the past month the price decreased by -21.87%. In the past year, price increased by 136.81%.
RVMD Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to RVMD. When comparing the yearly performance of all stocks, RVMD is one of the better performing stocks in the market, outperforming 96.47% of all stocks.
RVMD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RVMD. The financial health of RVMD is average, but there are quite some concerns on its profitability.
RVMD Financial Highlights
Over the last trailing twelve months RVMD reported a non-GAAP Earnings per Share(EPS) of -5.17. The EPS decreased by -44.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.65% | ||
| ROE | -37.58% | ||
| Debt/Equity | 0.16 |
RVMD Forecast & Estimates
27 analysts have analysed RVMD and the average price target is 115.71 USD. This implies a price increase of 20.15% is expected in the next year compared to the current price of 96.31.
For the next year, analysts expect an EPS growth of -59.94% and a revenue growth 1279.08% for RVMD
RVMD Ownership
RVMD Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.94 | 409.148B | ||
| AMGN | AMGEN INC | 16.38 | 198.801B | ||
| GILD | GILEAD SCIENCES INC | 17.38 | 192.281B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.11 | 124.696B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.29 | 84.911B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.93 | 41.535B | ||
| INSM | INSMED INC | N/A | 31.724B | ||
| BIIB | BIOGEN INC | 12.92 | 28.841B | ||
| NTRA | NATERA INC | N/A | 28.695B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.07 | 20.396B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RVMD
Company Profile
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. The company is headquartered in Redwood City, California and currently employs 809 full-time employees. The company went IPO on 2020-02-13. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
Company Info
REVOLUTION MEDICINES INC
700 Saginaw Dr
Redwood City CALIFORNIA 94063 US
CEO: Mark A. Goldsmith
Employees: 809
Phone: 13026365400
REVOLUTION MEDICINES INC / RVMD FAQ
What does REVOLUTION MEDICINES INC do?
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. The company is headquartered in Redwood City, California and currently employs 809 full-time employees. The company went IPO on 2020-02-13. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
What is the current price of RVMD stock?
The current stock price of RVMD is 96.31 USD. The price decreased by -1.05% in the last trading session.
Does REVOLUTION MEDICINES INC pay dividends?
RVMD does not pay a dividend.
What is the ChartMill technical and fundamental rating of RVMD stock?
RVMD has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in REVOLUTION MEDICINES INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on RVMD.
Can you provide the market cap for REVOLUTION MEDICINES INC?
REVOLUTION MEDICINES INC (RVMD) has a market capitalization of 18.62B USD. This makes RVMD a Large Cap stock.
Can you provide the ownership details for RVMD stock?
You can find the ownership structure of REVOLUTION MEDICINES INC (RVMD) on the Ownership tab.